Drug Discovery · London, United Kingdom · Founded 2019 · Privately Held (backing)
Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. Alchemab Therapeutics is based in London, United Kingdom and was founded in 2019. It was valued at $138 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $32.1 million across 1 recorded round; the latest was a $31.9 million Series A in Sep 2025.
PMV mark · valuation
$138.0M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$32.1M
Last round
Later Stage VC (Series A)
Sep 2025
Cap table — not yet on record
Alchemab Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Alchemab Therapeutics with a free account
·The complete investor list: 11 names
·Watch Alchemab Therapeutics: the Monday email on marks, rounds and moves
Where does Alchemab Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Alchemab Therapeutics's 1 recorded funding rounds.
